Development and Validation of Quality Measures for Testosterone Prescribing

• Published in: Journal of the Endocrine Society 2023-06, Vol.7 (7), p.bvad075
• Main Authors: Borzecki, Ann M, Conti, Jennifer, Reisman, Joel I, Vimalananda, Varsha, Nagy, Michael W, Paluri, Radhika, Linsky, Amy M, McCullough, Megan, Bhasin, Shalender, Matsumoto, Alvin M, Jasuja, Guneet K
• Format: Article
• Language: English
• Subjects: Associations, institutions, etc; Electronic records; Evidence-based medicine; Follicle-stimulating hormone; Glycoproteins; Health care reform; Luteinizing hormone; Medical care; Medical records; Prescription writing; Quality management; Societies; Stroke (Disease); Testosterone
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvad075

Abstract Context Accurate measures to assess appropriateness of testosterone prescribing are needed to improve prescribing practices. Objective This work aimed to develop and validate quality measures around the initiation and monitoring of testosterone prescribing. Methods This retrospective cohort study comprised a national cohort of male patients receiving care in the Veterans Health Administration who initiated testosterone during January or February 2020. Using laboratory data and diagnostic codes, we developed 9 initiation and 7 monitoring measures. These were based on the current Endocrine Society guidelines supplemented by expert opinion and prior work. We chose measures that could be operationalized using national VA electronic health record (EHR) data. We assessed criterion validity for these 16 measures by manual review of 142 charts. Main outcome measures included positive and negative predictive values (PPVs, NPVs), overall accuracy (OA), and Matthews Correlation Coefficients (MCCs). Results We found high PPVs (>78%), NPVs (>98%), OA (≥94%), and MCCs (>0.85) for the 10 measures based on laboratory data (5 initiation and 5 monitoring). For the 6 measures relying on diagnostic codes, we similarly found high NPVs (100%) and OAs (≥98%). However, PPVs for measures of acute conditions occurring before testosterone initiation (ie, acute myocardial infarction or stroke) or new conditions occurring after initiation (ie, prostate or breast cancer) PPVs were much lower (0% to 50%) due to few or no cases. Conclusion We developed several valid EHR-based quality measures for assessing testosterone-prescribing practices. Deployment of these measures in health care systems can facilitate identification of quality gaps in testosterone-prescribing and improve care of men with hypogonadism.